Generalized bullous fixed drug eruption

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD medical weight loss NYC and sleep center NYC

Generalized bullous fixed drug eruption
Generalized bullous fixed drug eruption
Synonyms	N/A
Pronounce	N/A
Specialty	N/A
Symptoms	Bullae, erythema, pruritus
Complications	Secondary infection, scarring
Onset	Hours to days after drug exposure
Duration	Days to weeks
Types	N/A
Causes	Drug reaction
Risks	Previous drug reactions, certain medications
Diagnosis	Clinical diagnosis, skin biopsy
Differential diagnosis	Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme
Prevention	Avoidance of triggering drugs
Treatment	Discontinuation of the offending drug, topical corticosteroids, antihistamines
Medication	N/A
Prognosis	Generally good with treatment
Frequency	Rare
Deaths	N/A

Generalized bullous fixed drug eruption (GBFDE) is a severe form of fixed drug eruption (FDE) characterized by widespread, recurrent bullous skin lesions triggered by the administration of specific medications. It is considered a severe cutaneous adverse reaction (SCAR) and may resemble other life-threatening conditions such as toxic epidermal necrolysis (TEN).

Pathophysiology

GBFDE is a delayed hypersensitivity reaction mediated by cytotoxic T cells in the epidermis. Upon re-exposure to the offending drug, memory T cells residing in the skin trigger a localized inflammatory response, leading to:

• Keratinocyte apoptosis – Resulting in blister formation.
• Widespread erythema – Red, inflamed skin patches.
• Recurrent lesions – Occurring at the same anatomical sites with repeated drug exposure.

The underlying mechanism involves drug-specific CD8+ T cells, which remain in the skin after the first exposure and reactivate upon rechallenge.

Causes and Triggers

Several medications have been implicated in causing generalized bullous fixed drug eruptions. The most commonly associated drugs include:

• Nonsteroidal anti-inflammatory drugs (NSAIDs) – Such as ibuprofen and naproxen.
• Antibiotics – Particularly sulfonamides, tetracyclines, and fluoroquinolones.
• Antiepileptic drugs – Including carbamazepine and phenytoin.
• Acetaminophen – A common over-the-counter pain reliever.
• Barbiturates – Previously implicated in severe reactions.

Clinical Features

Generalized bullous fixed drug eruption typically presents as:

• Painful, erythematous macules – Dark red or violaceous patches that appear within hours to days after drug intake.
• Blistering and bullae formation – Lesions progress to large fluid-filled blisters, which rupture and leave post-inflammatory hyperpigmentation.
• Mucosal involvement – Affecting the oral mucosa, genital mucosa, and sometimes the conjunctiva.
• Recurrent nature – Lesions reappear at the same sites upon re-exposure to the causative drug.

Unlike toxic epidermal necrolysis, GBFDE has well-demarcated lesions with less systemic involvement, although severe cases may mimic Stevens-Johnson syndrome.

Diagnosis

The diagnosis of GBFDE is primarily clinical, based on:

• History of drug exposure – Identifying recent use of potential causative medications.
• Skin biopsy findings:
• Epidermal necrosis and vacuolar interface dermatitis.
• Perivascular lymphocytic infiltrate in the dermis.
• Pigment incontinence (melanin-laden macrophages).

To confirm the diagnosis, a drug provocation test or patch testing may be performed, although these are reserved for specialized cases due to the risk of severe reactions.

Differential Diagnosis

GBFDE should be distinguished from other serious drug-induced cutaneous reactions, such as:

• Toxic epidermal necrolysis (TEN) – Widespread skin detachment with systemic involvement.
• Stevens-Johnson syndrome (SJS) – Severe mucocutaneous reaction with necrosis.
• Erythema multiforme – Target lesions with mucosal involvement but without epidermal detachment.
• Bullous pemphigoid – Autoimmune blistering disease affecting the elderly.

Treatment and Management

The primary treatment for generalized bullous fixed drug eruption involves:

• Immediate withdrawal of the offending drug – Essential to prevent progression and recurrence.
• Supportive care:
• Wound care – Similar to burn management in extensive cases.
• Pain relief – With topical corticosteroids and systemic analgesics.
• Antiseptic dressings – To prevent secondary infection.
• Systemic corticosteroids – Used in severe or widespread cases to reduce inflammation.
• Topical treatments – Corticosteroids and antihistamines to manage itching and discomfort.

Patients should be advised to avoid re-exposure to the offending drug, and medical alert identification may be recommended.

Prognosis

Most cases of generalized bullous fixed drug eruption resolve within weeks after discontinuation of the causative medication. However, recurrent exposure can lead to severe, widespread skin damage and increased pigmentation changes. Early identification and drug avoidance are crucial to preventing complications.

Prevention

To prevent recurrence:

• Avoidance of known trigger drugs – Patients should keep a record of past reactions.
• Drug allergy testing – In suspected cases where the culprit drug is uncertain.
• Medication alert bracelets – For individuals with a history of severe drug reactions.

See also

• Fixed drug eruption
• Stevens-Johnson syndrome
• Toxic epidermal necrolysis
• Drug allergy
• Bullous drug reaction

   This article is a dermatology stub. You can help WikiMD by expanding it!